OncoMatch/Clinical Trials/NCT03997643
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
Is NCT03997643 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for head and neck cancer.
The goal of this randomized treatment study is to formally compare quality of life in patients with at least one pN0 hemi-neck after resection of a squamous cell carcinoma of the oral cavity treated with a primary radiation therapy versus a secondary targeted radiation therapy approach, to provide a high level of evidence to guide the selection of treatment options.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage PT3, PT4
pT3 or pT4 disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — oral cavity and at least ipsilateral selective neck dissection
resected oral cavity squamous cell carcinoma with at least ipsilateral selective neck dissection
Cannot have received: radiation therapy
Prior head and neck radiation at any time
Cannot have received: surgery
Prior oncologic head and neck surgery in the oral cavity or neck
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Miami Cancer Institute · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03997643 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, surgery disqualifies patients from enrollment.
What disease stage is eligible?
Stage PT3 or PT4 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages